Puffiness and fluid retention in the hands and feet, joint aches, wrist tingling (carpal tunnel), and blood sugar creeping up over weeks — most pronounced with MK-677 and somatropin.
These accumulate rather than strike suddenly — reassess and stop rather than pushing the dose up. Check glucose if you can.
A severe persistent headache with vision changes (possible raised intracranial pressure), or symptoms of very high blood sugar — extreme thirst, confusion, vomiting — warrant urgent care.
Allergic reaction: hives, swelling of the lips, tongue or throat, wheezing or dizziness can escalate to anaphylaxis within minutes — call 911 immediately. Site infection: spreading redness, heat, swelling, pus or fever is not wait-and-see; an abscess or cellulitis can need drainage or IV antibiotics. Unverified product: grey-market vials are frequently mislabelled or contaminated, so a reaction may be to endotoxin or the wrong contents, not the named compound.
A small-molecule ghrelin receptor agonist that is orally bioavailable — the reason it is grouped with the injectable GHRPs despite sharing none of their chemistry. It raises GH and IGF-1 in a sustained rather than pulsatile fashion, and its long half-life means the elevation persists around the clock.
Better human data than most of this category. Merck developed it through multiple trials, including a two-year study in older adults showing sustained IGF-1 elevation and increased lean mass. Development was ultimately abandoned. A trial in hip-fracture rehabilitation was discontinued after congestive heart failure signals.
Not FDA-approved. Never approved anywhere. Not a lawful dietary supplement — FDA has issued warning letters to companies marketing it as one. Prohibited in sport (WADA S2).
The signals here are concrete rather than theoretical. Trials reported increased fasting glucose and reduced insulin sensitivity, oedema, arthralgia, and an increase in congestive heart failure in one older-adult population. Sustained appetite stimulation is pronounced. The abandoned development programme reflects these findings, not a lack of interest.
Studied at 25 mg once daily, oral, in Merck trials including a two-year older-adult study. Never approved — the same trials surfaced raised blood glucose and, in one population, increased heart failure.
Reported from clinical trials or FDA labelling as a matter of record. It is not a recommendation, and for unapproved compounds no dose has been shown safe or effective in humans.
Above is what was administered in trials or on FDA labels, reported as fact. We do not convert it into a personal protocol, calculate a dose for your body weight, or tell you what to inject or how to reconstitute it — that decision belongs with a licensed physician. See our editorial policy.
Regulatory status changes. This page reflects our reading of public sources as of July 2026 and should be independently verified before it is relied upon.